Journal article
P119 Design of a randomized, open-label trial adding custirsen, a novel clusterin inhibitor, to cabazitaxel/prednisone in second-line treatment of metastatic Castration-Resistant Prostate Cancer (mCRPC): The AFFINITY phase 3 study
Authors
Beer TM; Blumenstein BA; Fizazi K; Hotte SJ; Jacobs C; Stewart PS
Journal
European Urology Open Science, Vol. 12, No. 6,
Publisher
Elsevier
Publication Date
11 2013
DOI
10.1016/s1569-9056(13)62443-4
ISSN
2666-1691